Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
Bidders seem to be dropping like flies and it's unclear just who is left in the auction
The company provides real-time feedback on not-for-profit organisations, offering a breakthrough for the charities, companies and government departments that fund them
Hikma hit a roadblock with the US Food & Drug Administration as it lodged an abbreviated new drug application for asthma treatment Advair Diskus, first developed by GlaxoSmithKline
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
The miner acquired a 50% stake in the Alaskan asset back in July along with its purchase of Zazu Metals.
HC Wainwright reckons the stock is worth US$30, which compares with the current price of US$17..
Proactive's early take on the day's small-cap news ...
Numis has initiated coverage of Lydian with a 'buy' rating and target price of 80 cents